Oppenheimer & Co’s Regulus Therapeutics RGLS Stock Holding History

Oppenheimer & Co’s Portfolio RGLS Stock Details RGLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-55,000	Closed	-$96.3K	–	1682
2025 Q1	$96.3K	Buy	+55,000	New	+$72.6K	﹤0.01%	1520

Other funds holding RGLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Oppenheimer & Co's RGLS Position: Q2 2025 in Review

Oppenheimer & Co sold out of Regulus Therapeutics (RGLS) in Q2 2025, closing a stake of 55,000 shares — an estimated $96.3K sold.

Oppenheimer & Co first reported a position in RGLS in Q1 2025 and held it in 1 quarter. The position peaked at $96.3K in Q1 2025. 0 funds tracked by Wall St. Rank hold RGLS as of Q2 2025.

Oppenheimer & Co reported no remaining Regulus Therapeutics position as of Q2 2025 after selling out during the quarter.
Oppenheimer & Co sold 55,000 Regulus Therapeutics shares in Q2 2025, an estimated $96.3K.
Oppenheimer & Co first reported a position in Regulus Therapeutics in Q1 2025 and held it in 1 quarter.
Oppenheimer & Co's Regulus Therapeutics position peaked at $96.3K in Q1 2025.
0 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q2 2025.

Based on Oppenheimer & Co's 13F filing for Q2 2025, filed 31 Jul 2025.